CYTOF
Price
$0.07
Change
-$0.01 (-11.11%)
Updated
Jul 3 closing price
Capitalization
349.66K
SPHDF
Price
$14.75
Change
-$1.15 (-7.23%)
Updated
May 28 closing price
Capitalization
197.19M
Interact to see
Advertisement

CYTOF vs SPHDF

Header iconCYTOF vs SPHDF Comparison
Open Charts CYTOF vs SPHDFBanner chart's image
Altamira Therapeutics
Price$0.07
Change-$0.01 (-11.11%)
Volume$8.3K
Capitalization349.66K
Santhera Pharmaceuticals Holdings
Price$14.75
Change-$1.15 (-7.23%)
Volume$285
Capitalization197.19M
CYTOF vs SPHDF Comparison Chart in %
Loading...
CYTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTOF vs. SPHDF commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTOF is a Hold and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (CYTOF: $0.08 vs. SPHDF: $14.75)
Brand notoriety: CYTOF and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTOF: 94% vs. SPHDF: 137%
Market capitalization -- CYTOF: $349.66K vs. SPHDF: $197.19M
CYTOF [@Biotechnology] is valued at $349.66K. SPHDF’s [@Biotechnology] market capitalization is $197.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTOF’s FA Score shows that 1 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • CYTOF’s FA Score: 1 green, 4 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHDF is a better buy in the long-term than CYTOF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTOF’s TA Score shows that 2 TA indicator(s) are bullish while SPHDF’s TA Score has 2 bullish TA indicator(s).

  • CYTOF’s TA Score: 2 bullish, 6 bearish.
  • SPHDF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, SPHDF is a better buy in the short-term than CYTOF.

Price Growth

CYTOF (@Biotechnology) experienced а -25.00% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CYTOF is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHDF($197M) has a higher market cap than CYTOF($350K). SPHDF has higher P/E ratio than CYTOF: SPHDF (2.53) vs CYTOF (0.05). SPHDF YTD gains are higher at: 56.582 vs. CYTOF (-32.127).
CYTOFSPHDFCYTOF / SPHDF
Capitalization350K197M0%
EBITDAN/AN/A-
Gain YTD-32.12756.582-57%
P/E Ratio0.052.532%
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CYTOF vs SPHDF: Fundamental Ratings
CYTOF
SPHDF
OUTLOOK RATING
1..100
6843
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6548
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTOF's Valuation (8) in the Biotechnology industry is somewhat better than the same rating for SPHDF (60) in the null industry. This means that CYTOF’s stock grew somewhat faster than SPHDF’s over the last 12 months.

CYTOF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SPHDF (100) in the null industry. This means that CYTOF’s stock grew similarly to SPHDF’s over the last 12 months.

CYTOF's SMR Rating (100) in the Biotechnology industry is in the same range as SPHDF (100) in the null industry. This means that CYTOF’s stock grew similarly to SPHDF’s over the last 12 months.

SPHDF's Price Growth Rating (48) in the null industry is in the same range as CYTOF (65) in the Biotechnology industry. This means that SPHDF’s stock grew similarly to CYTOF’s over the last 12 months.

SPHDF's P/E Growth Rating (12) in the null industry is significantly better than the same rating for CYTOF (100) in the Biotechnology industry. This means that SPHDF’s stock grew significantly faster than CYTOF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTOFSPHDF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
36%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
28%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
11%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
12%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
CYTOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADLVX29.16N/A
N/A
Adler Value Institutional
JIEZX21.90N/A
N/A
JPMorgan International Equity R2
PJEZX15.49N/A
N/A
PGIM US Real Estate Z
VSCNX21.14N/A
N/A
Natixis Vaughan Nelson Small Cap N
MKGCX29.00N/A
N/A
BlackRock Advantage Global K

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with TRML. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then TRML could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
TRML - SPHDF
78%
Closely correlated
+1.42%
COGT - SPHDF
63%
Loosely correlated
+2.29%
MEOBF - SPHDF
50%
Loosely correlated
N/A
KROS - SPHDF
38%
Loosely correlated
+0.30%
CYTOF - SPHDF
35%
Loosely correlated
-20.97%
More